Loading the content... Loading depends on your connection speed!

Shopping Cart - $0.00

Kidney Cancer Market Global Briefing 2017

Kidney Cancer Market Global Briefing 2017

From $1,000.00

Including: Drugs For – Renal Cell Carcinoma, Transitional Cell Carcinoma, Sarcoma, Wilms Tumor, And Lymphoma.
Covering: Bayer, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Pfizer Inc.


Clear selection
SKU: 2262. Category: .
Description

Kidney Cancer Market Global Briefing 2017 from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global kidney cancer market.

Description

The Kidney Cancer Market Global Briefing Report from The Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The kidney cancer market is one of the segments in the oncology drugs market, within the pharmaceutical drugs market.

The market characteristics section of the report defines and explains the market.

The market size section gives the kidney cancer market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the kidney cancer market and suggests approaches.

Reasons to Purchase

• Get up to date information available on the kidney cancer market globally.
• Identify growth segments and opportunities.
• Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
• Develop strategies based on likely future developments.
• Gain a global perspective on the development of the market.
• Report will be updated with the latest data and delivered to you within 2-3 working days of order.

Scope

Markets Covered: Drugs For – Renal Cell Carcinoma, Transitional Cell Carcinoma, Sarcoma, Wilms Tumor, And Lymphoma.

Companies Mentioned: Bayer, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Pfizer Inc.

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Market value in $ billions.

Data segmentations: Regional breakdowns, market share of competitors, key sub segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Related Reports:
Lung cancer Market Global Briefing 2017
Pancreatic cancer Market Global Briefing 2017
Breast cancer Market Global Briefing 2017
Prostate cancer Market Global Briefing 2017
Ovarian cancer Market Global Briefing 2017
Gastric Cancer Market Global Briefing 2017
Non-Small Cell Lung Cancer Market Global Briefing 2017
Brain Tumor Market Global Briefing 2017
Colorectal Cancer Market Global Briefing 2017
Thyroid cancer Market Global Briefing 2017
Bladder Cancer Market Global Briefing 2017
Skin cancer Market Global Briefing 2017
Cervical Cancer Market Global Briefing 2017
Blood cancer Market Global Briefing 2017

Table Of Contents
Table Of Contents

1. Introduction
2. Kidney Cancer Market Characteristics
3. Kidney Cancer Market Historic Growth
• Drivers Of The Market
• Restraints On The Market
4. Kidney Cancer Market Forecast Growth
• Drivers Of The Market
• Restraints On The Market
5. Kidney Cancer Market Geography Split
6. Kidney Cancer Market As A Proportion of Oncology Drugs Market, 2016, By Region
7. Kidney Cancer Market As A Proportion of Oncology Drugs Market, 2016, By Country
8. Kidney Cancer Market Segmentation
9. Kidney Cancer Competitive Landscape
Bayer
F. Hoffmann-La Roche
GlaxoSmithKline
Novartis
Pfizer Inc.
10. Key Mergers And Acquisitions In The Kidney Cancer Market
11. Kidney Cancer Market Trends And Strategies
Appendix
NAICS Definitions of Industry Covered In This Report
Research Methodology
Methodology
Data
Market Numbers
Competitor Market Share Data
Analysis
Verification Through Expert Interviews
Referencing
Note on Currency Conversions
Abbreviations
Currencies
Research Inquiries
The Business Research Company

List Of Tables
Table 1: Global Kidney Cancer Market Historic Market Size, 2012 – 2016, $ Billion
Table 2: Global Kidney Cancer Market Forecast Market Size, 2016 – 2020, $ Billion
Table 3: Global Kidney Cancer Market, Split By Region, 2016, $ Billion
Table 4: Kidney Cancer Market As A Proportion of Oncology Drugs Market, 2016, By Region
Table 5: Kidney Cancer Market As A Proportion of Oncology Drugs Market, 2016, By Country
Table 6: Global Kidney Cancer Market, Key Competitor Shares, 2016, Percentage (%)
Table 7: Global Kidney Cancer Market, Split By Segments, 2016, $ Billion

List Of Figures
Figure 1: Global Kidney Cancer Market Historic Market Size, 2012 – 2016, $ Billion
Figure 2: Global Kidney Cancer Market Forecast Market Size, 2016 – 2020, $ Billion
Figure 3: Global Kidney Cancer Market, Split By Region, 2016, $ Billion
Figure 4: Kidney Cancer Market As A Proportion of Oncology Drugs Market, 2016, By Region
Figure 5: Kidney Cancer Market As A Proportion of Oncology Drugs Market, 2020, By Country
Figure 6: Global Kidney Cancer Market, Key Competitor Shares, 2016, Percentage (%)
Figure 7: Global Kidney Cancer Market, Split By Segments, 2016, $ Billion
Executive Summary
The kidney cancer drugs market cover drugs that treat cancer related to kidney. These indications include renal cell carcinoma, transitional cell carcinoma, sarcoma, Wilms tumor, and lymphoma. Some of the major drugs in this market are Votrient (Pazopanib), Torisel (Temsirolimus), Sutent (Sunitinib), Proleukin (Aldesleukin), Nexavar (Sorafenib), Inlyta (Axitinib), Avastin (Bevacizumab), and Afinitor (Everolimus). Based on the drug class, the market is segmented into two segments: multikinase inhibitors and other RCC drug classes (including immunomodulators, mTOR inhibitors, and other emerging drug classes).

The global kidney cancer market was estimated to be around $3.1 billion as of 2016. The global kidney cancer made up around 3% of the overall oncology drugs market in 2016. The kidney cancer market was the eighth largest market in the global oncology drugs market in 2016.

Regulatory Approvals
Continous approvals from regulatory bodies such as FDA in the US and EMA in Europe is one of the major trend in this market. For instance, in April 2016, Exelixis received FDA approval for its Cabometyx cancer drug that is used in the treatment of renal cell carcinoma. In December 2015, Bristol-Myers Squibb received FDA approval for its Opdivo drug which is used as a second line treatment of renal cell carcinoma.
Get Customized Report
Please fill in your details. Our team will get back to you